Y
Yan Sun
Researcher at Peking Union Medical College
Publications - 186
Citations - 14089
Yan Sun is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 34, co-authored 161 publications receiving 11894 citations. Previous affiliations of Yan Sun include Peking University & Huazhong University of Science and Technology.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim,Vera Hirsh,Tony Mok,Mark A. Socinski,Radj Gervais,Yi-Long Wu,Long Yun Li,Claire Watkins,Mark V. Sellers,Elizabeth S. Lowe,Yan Sun,Mei Lin Liao,Kell Østerlind,Martin Reck,Alison Armour,Frances A. Shepherd,Scott M. Lippman,Jean-Yves Douillard +17 more
TL;DR: Non-inferior survival of gefitinib compared with docetaxel is established, suggesting that gef itinib is a valid treatment for pretreated patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller,Vincent A. Miller,Vera Hirsh,Jacques Cadranel,Yuh Min Chen,Keunchil Park,Sang We Kim,Caicun Zhou,Wu Chou Su,M. Wang,Yan Sun,Dae Seog Heo,Lucio Crinò,Eng Huat Tan,Tsu Yi Chao,Mehdi Shahidi,X.J. Cong,Robert M. Lorence,James Chih-Hsin Yang +18 more
TL;DR: The findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.
Journal ArticleDOI
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
Ying Sun,Wen Fei Li,Nian Yong Chen,Ning Zhang,Guoqing Hu,Fang Yun Xie,Yan Sun,Xiao Zhong Chen,Jin Gao Li,Xiao-Dong Zhu,Chaosu Hu,Xiang Ying Xu,Yuan Yuan Chen,Wei Han Hu,Ling Guo,Hao Yuan Mo,Lei Chen,Yan Ping Mao,Rui Sun,Ping Ai,Shao Bo Liang,Guo Xian Long,Bao Min Zheng,Xing Lai Feng,Xiao Chang Gong,Ling Li,Chun Ying Shen,Jian Yu Xu,Ying Guo,Yu Ming Chen,Fan Zhang,Li Lin,Ling Long Tang,Meng Zhong Liu,Jun Ma +34 more
TL;DR: Addition of TPF induction chemotherapy to concurrent chemoradiotherapy significantly improved failure-free survival in locoregionally advanced nasopharyngeal carcinoma with acceptable toxicity.
Journal ArticleDOI
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
Yuan Zhang,Lei Chen,Guoqing Hu,Ning Zhang,Xiao-Dong Zhu,Kunyu Yang,Feng Jin,Mei Shi,Yu Pei Chen,Weihan Hu,Zhi-Bin Cheng,Si-Yang Wang,Ye Tian,Xicheng Wang,Yan Sun,Jin-Gao Li,Wen-Fei Li,Yu-Hong Li,Ling-Long Tang,Yan Ping Mao,Guan-Qun Zhou,Rui Sun,Xu Liu,Rui Guo,Guo-Xian Long,Shao-Qiang Liang,Ling Li,Jing Huang,Jin-Hua Long,Jian Zang,Qiao-Dan Liu,Li Zou,Qiong-Fei Su,Bao-Min Zheng,Yun Xiao,Ying Guo,Fei Han,Hao-Yuan Mo,Jia-Wei Lv,Xiao-Jing Du,Cheng Xu,Na Liu,Ying-Qin Li,Melvin L.K. Chua,Fang-Yun Xie,Ying Sun,Jun Ma +46 more
TL;DR: Induction chemotherapy added to chemoradiotherapy significantly improved recurrence-free survival and overall survival, as compared with chemoradaotherapy alone, among patients with locoregionally advanced nasopharyngeal carcinoma.